Foundation Medicine Announces Details of Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

New studies demonstrate the unique capabilities of Foundation Medicine’s monitoring assays, FoundationOne®Tracker and FoundationOne®Monitor

Additional research highlights the ability of Foundation Medicine’s high-quality genomic profiling tests to predict immunotherapy response and investigate how differences in genetic ancestry may impact cancer care

Foundation Medicine, Inc., a genomics company dedicated to transforming cancer care, today announced that research from its robust oncology diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California April 5-10, 2024.

The presentations include new research from Foundation Medicine’s two circulating tumor DNA (ctDNA) monitoring tests – FoundationOne®Tracker and the research use version of FoundationOne®Monitor – demonstrating the value of the company’s diverse portfolio of tissue-informed and tissue-naïve assays to support cancer treatment response monitoring. Highlights include:

• In a retrospective study of 58 patients from the Genentech, a member of the Roche Group, MyPathway study (NCT02091141), tissue-informed early ctDNA monitoring using the clinically available FoundationOne Tracker test provided insight into treatment response and survival outcomes in patients across diverse HER2 amplified or mutated tumors receiving HER2 ​targeted​ therapy. ​Results suggest ​serial early ctDNA monitoring ​is a valuable complementary tool for real-time treatment response monitoring to targeted therapy. (Mini-symposium presented by Razelle Kurzrock, MD: Biomarkers Predictive of Therapeutic Benefit; Abstract #1209)

• Leveraging plasma collected serially from patients in Genentech’s Prospective Clinico-Genomic (PCG) study (NCT04180176), the FoundationOne Monitor assay was used to investigate ctDNA tumor fraction for monitoring treatment response. The test’s highly specific algorithmic filtration of non-tumor signal (such as clonal hematopoiesis) enabled high confidence in ctDNA quantification and assessment of molecular response. These findings may enable personalized therapy approaches tailored to a patient’s risk of progression and downstream cancer treatment planning. (Poster #971)

Additional presentations focused on the value of genomic profiling in non-small cell lung cancer (NSCLC) include data on how tumor microenvironment (TME) impacts immunotherapy response and an ancestry-based genomic landscape study. Highlights include:

• The composition of TME has been shown to influence response to immunotherapy. Using artificial intelligence, Foundation Medicine researchers investigated digital pathology TME features of immunotherapy outcomes among patients with non-squamous NSCLC within a real-world dataset from the Flatiron Health-Foundation Medicine Clinico-Genomic Database. These results indicate that the composition of the TME assessed via digital pathology may have utility in identifying NSCLC patients who will respond to first-line immune checkpoint inhibitors beyond the established immunotherapy biomarkers. (Poster #4969)
• Racial and ethnic disparities are highly prevalent in cancer care and impact treatment outcomes. Foundation Medicine remains committed to studying how ancestral differences in genomic alterations may impact patient care. In this study, researchers conducted a comprehensive characterization of the ancestry-based genomic co-alteration landscape and patterns of immunotherapy-related biomarkers in KRAS and EGFR-altered non-squamous NSCLC tumors. (Poster #6120)

“We’re excited to present new data at AACR reinforcing the diverse utility of our monitoring portfolio to help confirm that patients are on the right targeted therapies and immunotherapies for the right amount of time,” says Mia Levy, MD, PhD, Chief Medical Officer at Foundation Medicine. “Additionally, we know that the impact of genetic ancestry on the genomic landscape of tumors remains understudied, and we are always proud to demonstrate our dedication to closing more gaps in these disparities in cancer care.”

Additionally, Dr. Levy will be taking part in a plenary session on Wednesday, April 10 titled “AI at the Interface: Accelerating Evidence Generation, Advancing Disparities Research, and Improving Trial Design.” The following is a list of the presentations, along with their viewing details. To access all abstracts being presented at AACR, please visit aacr.org.

Follow Foundation Medicine on LinkedIn and X for more updates from #AACR24 and visit us in person at booth #3117.

About Foundation Medicine: Your Essential Partner in Cancer Care

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on Twitter and LinkedIn.

Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306582349/en/